reports
Iridex Reports Fourth Quarter and Full Year 2023 Financial Results
Iridex Reports Fourth Quarter and Full Year 2023 Financial Results Advances strategic review to unlock shareholder value MOUNTAIN VIEW, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the fourth quarter and full year ended December 30, 2023, and provided a business update. Fourth Quarter 2023 Results & Recent Highlights Generated total reve...
Iridex Schedules Fourth Quarter and Full Year 2023 Financial Results a...
Iridex Schedules Fourth Quarter and Full Year 2023 Financial Results and Update on Strategic Review Process for March 26, 2024 MOUNTAIN VIEW, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced it will release financial results for the fourth quarter and full year 2023 and provide an update on its strategic review process after the close of trading on Tuesday, March 26, 2024. ...
Iridex Corporation Receives European Patent on MicroPulse Technology
Iridex Corporation Receives European Patent on MicroPulse Technology The Advanced Short Pulse Laser System MOUNTAIN VIEW, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the grant of the European Patent EP 3009093, entitled "Laser System with Short Pulse Characteristics and its Methods of Use”. This groundbreaking patent further protects Iridex’s intellectual property enc...
Iridex Announces First Patient Enrollment in MicroPulse® TLT Clinical ...
Iridex Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust MOUNTAIN VIEW, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation, headquartered in Mountain View, California, and Imperial College Healthcare NHS Trust in London, today announced the first patient enrollment in a collaborative medical research study and registry evaluating the treatment of glaucoma with MicroPulse® Transscleral Laser Therapy (TLT) using Iridex’ Cyclo G6® Laser and the MicroPulse P3® Delivery Device. This partnership e...
Iridex Launches New Iridex 532® and Iridex 577® Lasers in US Market Ma...
Iridex Launches New Iridex 532® and Iridex 577® Lasers in US Market Marking 35 Years of Laser Innovation in Treating Retina Disorders & Glaucoma MOUNTAIN VIEW, Calif., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation, a global leader in innovative laser-based medical systems for the treatment of eye diseases, proudly announces the US launch of its next-generation platform Iridex 532® and Iridex 577® Lasers alongside its 35th anniversary celebration. The announcement was made ahead of their official showcase at the Hawaiian Eye and Retina 2024 Meeting from January 13-19, 2024. Both la...
Iridex Confirms Medicare Administrative Contractors Retired Local Cove...
Iridex Confirms Medicare Administrative Contractors Retired Local Coverage Determinations that Restricted Cyclophotocoagulation Action Retains Full Patient Access to MicroPulse® Transscleral Laser Treatment MOUNTAIN VIEW, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced all five Medicare Administrative Contractors (“MACs”) retired their local coverage determinations (“LCDs...
Iridex Corporation Announces Successful Appeal for Revision of Recent ...
Iridex Corporation Announces Successful Appeal for Revision of Recent Medicare LCDs to Provide Broader Coverage of Cyclophotocoagulation MOUNTAIN VIEW, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced its successful advocacy for revision of the recently issued Medicare Local Coverage Determinations (LCDs) for Cyclophotocoagulation (CPC). During the last few days, the five M...
Iridex Reports Third Quarter 2023 Financial Results and Business Updat...
Iridex Reports Third Quarter 2023 Financial Results and Business Update MOUNTAIN VIEW, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a business update. Recent Business Updates Generated total revenue of $12.9 million, representing flat sequential quarter revenue and a decrease of 12% year-over...
Iridex to Host Third Quarter Financial Results Conference Call on Nove...
Iridex to Host Third Quarter Financial Results Conference Call on November 14, 2023 The Company also announced plans to present at Stifel Healthcare Conference MOUNTAIN VIEW, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will host its third quarter financial results conference call on November 14, 2023 and plans to participate in the upcoming Stifel Healthcare Conference on November 15, 2023 in New York, NY. Th...
Iridex to Report Third Quarter Financial Results on November 14, 2023
Iridex to Report Third Quarter Financial Results on November 14, 2023 MOUNTAIN VIEW, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter of 2023 after the close of trading on Tuesday, November 14, 2023. About IridexIridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery device...
Iridex Announces Strategic Review to Unlock Shareholder Value
Iridex Announces Strategic Review to Unlock Shareholder Value MOUNTAIN VIEW, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) announced today that its Board of Directors is undertaking, in consultation with its financial and legal advisors, a review and evaluation of strategic alternatives that may be available to the Company to unlock shareholder value. Iridex has engaged Piper Sandler to act as financial advisor in connection with the strategic review process. “Iridex is a worldwide leader in laser-based medical systems for the ophthalmology market, with prov...
Iridex Reports Second Quarter 2023 Financial Results
Iridex Reports Second Quarter 2023 Financial Results MOUNTAIN VIEW, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today reported financial results for the second quarter ended July 1, 2023. Second Quarter 2023 Highlights Generated total revenue of $12.9 million, a decrease of 7% year-over-yearCyclo G6® product family revenue of $3.7 million increased 5% year-over-year 41 Cyclo G6 Glaucoma Laser Systems sold, compared to 48 in the prior...
Iridex to Report Second Quarter Financial Results on August 10, 2023
Iridex to Report Second Quarter Financial Results on August 10, 2023 MOUNTAIN VIEW, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the second quarter of 2023 after the close of trading on Thursday, August 10, 2023. The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference cal...
Iridex Reports First Quarter 2023 Financial Results
Iridex Reports First Quarter 2023 Financial Results MOUNTAIN VIEW, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended April 1, 2023. First Quarter 2023 Highlights Generated total revenue of $13.7 million, an increase of 2% year-over-yearCyclo G6® product family revenue of $3.7 million increased 4% year-over-year 61 Cyclo G6 Glaucoma Laser Systems sold, compared to 56 in the prior year p...
Iridex to Report First Quarter Financial Results on May 11, 2023
Iridex to Report First Quarter Financial Results on May 11, 2023 MOUNTAIN VIEW, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the first quarter of 2023 after the close of trading on Thursday, May 11, 2023. The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may...
Iridex Reports Fourth Quarter and Full Year 2022 Financial Results
Iridex Reports Fourth Quarter and Full Year 2022 Financial Results Achieves Record Quarterly Glaucoma Probe Sales and 6% Full Year Revenue Growth MOUNTAIN VIEW, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today reported financial results for the fourth quarter and year ended December 31, 2022 and issued 2023 financial guidance. Fourth Quarter 2022 & Recent Highlights Generated total revenue of $15.2 million, essentially unchanged from ...
Iridex to Present at the 35th Annual Roth Conference
Iridex to Present at the 35th Annual Roth Conference MOUNTAIN VIEW, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced plans to participate in the upcoming 35th Annual Roth Conference in Laguna Niguel, CA. Management is scheduled to present on Tuesday, March 14 at 11:00 am PT. Interested parties may access a live and archived webcast of the presentation on the “Event Calendar” page of the “Investors” section of the company’s websi...
Iridex Introduces New Research and Showcases Five Events at the AGS Me...
Iridex Introduces New Research and Showcases Five Events at the AGS Meeting Five Events at Booth #5 Discover the latest surgical techniques and outcomes published by the International MicroPulse TLT Consensus Panel.Watch Dr. Syril Dorairaj’s e-poster on prospective MicroPulse TLT dosimetry research outcomes.Demo Sweep Management Software for MicroPulse TLT.Celebrate AGS Innovator Award recipient Douglas Gaasterland, MD.Learn about our Advanced Surgeon Forum on MicroPulse TLT. MOUNTAIN VIEW, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innov...
Iridex to Report Fourth Quarter and Full Year 2022 Financial Results o...
Iridex to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023 MOUNTAIN VIEW, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the fourth quarter and full year 2022 after the close of trading on Thursday, March 9, 2023. The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in liste...
Iridex Announces Preliminary Operational and Financial Results for Fou...
Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2022 Achieves Record Quarterly Glaucoma Probe sales and 6% Full Year Revenue Growth MOUNTAIN VIEW, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today provided preliminary unaudited operational and financial results for the fourth quarter and full year ended December 31, 2022. Fourth Quarter 2022 Results Total revenue is expected to be between $...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.